scholarly journals Hereditary angioedema: experience of substitution therapy with a C1 esterase inhibitor in the Sverdlovsk region

2019 ◽  
Vol 16 (3) ◽  
pp. 61-66
Author(s):  
E K Beltyukov ◽  
S S Vedenskaya ◽  
I S Skorokhodov ◽  
V V Naumova ◽  
M V Beltyukova ◽  
...  

Hereditary angioedema (HAO) is rare disease, however, it's lifethreatening localization can be fatal. Antifibrinolytics and attenuated androgens used for the prevention of HAO attacks have side effects, which limit their use. The bradykinin B2 receptor antagonist, Icatybant is an effective but shortacting dmedication. The human C1 esterase inhibitor (berinert) is safe and effective for the prevention and relief of angioedema of lifethreatening localization, including in pregnant women. The management of patients with HAO is regulated by national guidelines, and the use of a human C1 esterase inhibitor is recommended by instruction of the drug and by the Ministry of Health of the Sverdlovsk region. Patients with HAO should be provided with patient’s passport and fill a diary of symptoms monitoring of HAO.

Author(s):  
E.K. Beltyukov ◽  
S.S. Vedenskaya ◽  
I.S. Skorokhodov ◽  
V.V. Naumova ◽  
M.V. Beltyukova ◽  
...  

Наследственный ангиоотек (НАО) встречается редко, тем не менее его жизнеугрожающая локализация может привести к летальному исходу. Применяемые для профилактики атак НАО антифибринолитики и аттенуированные андрогены обладают побочными действиями, что ограничивает их использование. Антагонист Р2рецепторов брадикинина икатибант является эффективным, но короткодействующим препаратом. Ингибитор С1 эстеразы человека (Беринерт) является безопасным и эффективным для профилактики и купирования ангиоотеков жизнеугрожающей локализации, в том числе у беременных женщин. Ведение больных НАО регламентировано национальными рекомендациями, а применение ингибитора С1 эстеразы человека инструкцией на препарат и письмом Минздрава Свердловской области. Больные с НАО должны при себе иметь паспорт пациента и дневник контроля симптомов НАО.Hereditary angioedema (HAO) is rare disease, however, its lifethreatening localization can be fatal. Antifibrinolytics and attenuated androgens used for the prevention of HAO attacks have side effects, which limit their use. The bradykinin B2 receptor antagonist, Icatybant is an effective but shortacting dmedication. The human C1 esterase inhibitor (berinert) is safe and effective for the prevention and relief of angioedema of lifethreatening localization, including in pregnant women. The management of patients with HAO is regulated by national guidelines, and the use of a human C1 esterase inhibitor is recommended by instruction of the drug and by the Ministry of Health of the Sverdlovsk region. Patients with HAO should be provided with patients passport and fill a diary of symptoms monitoring of HAO.


2013 ◽  
Vol 34 (2) ◽  
pp. 162-169 ◽  
Author(s):  
James W. Baker ◽  
Timothy J. Craig ◽  
Marc A. Riedl ◽  
Aleena Banerji ◽  
David Fitts ◽  
...  

2011 ◽  
Vol 4 ◽  
pp. CMBD.S4090 ◽  
Author(s):  
Solange Oliveira Rodrigues Valle ◽  
Alfeu Tavares França ◽  
Regis A. Campos ◽  
Anete Sevciovic Grumach

Hereditary angioedema (HAE) is a relatively rare disease characterized by acute episodes of swelling. These swellings can be disfiguring, painful and life-threatening. Since the symptoms occur in different areas and most patients experience a delay in their diagnosis, resulting in unnecessary suffering and dangerous situations. HAE can have a tremendous impact on the quality of life. The major genetic deficiency in this disorder is either an absent or nonfunctional C1INH which regulates the complement, fibrinolitic, kalikrein and plasmin pathways.


2016 ◽  
Vol 137 (2) ◽  
pp. AB243 ◽  
Author(s):  
James A. Fox ◽  
Inmaculada Martinez-Saguer ◽  
Arthur B. Vegh ◽  
Walter A. Wuillemin ◽  
Jonathan M. Edelman ◽  
...  

Author(s):  
Marco Cicardi ◽  
Lorenza Zingale ◽  
Andrea Zanichelli ◽  
Daniela Lambertenghi Deliliers

2021 ◽  
Vol 14 (4) ◽  
pp. 100535
Author(s):  
Anna Valerieva ◽  
Maria T. Staevska ◽  
Vesna Grivcheva-Panovska ◽  
Milos Jesenak ◽  
Kinga Viktória Kőhalmi ◽  
...  

2014 ◽  
Vol 2 (1) ◽  
pp. 77-84.e1 ◽  
Author(s):  
Jonathan A. Bernstein ◽  
Michael E. Manning ◽  
Henry Li ◽  
Martha V. White ◽  
James Baker ◽  
...  

2011 ◽  
Vol 4 ◽  
pp. S9-S21 ◽  
Author(s):  
Richard G Gower ◽  
Paula J Busse ◽  
Emel Aygören-Pürsün ◽  
Amin J Barakat ◽  
Teresa Caballero ◽  
...  

2021 ◽  
Vol 42 (4) ◽  
pp. 317-324
Author(s):  
Felix. A. Johnson ◽  
Magdalena Wirth ◽  
Zhaojun Zhu ◽  
Janina Hahn ◽  
Jens Greve ◽  
...  

Introduction: Hereditary angioedema (HAE) is a disease that leads to recurrent swelling of the skin and mucous membranes, including the upper airway tract. Apart from being deadly, these attacks can be debilitating, which leads to a poor quality of life in patients. Clinicians are occasionally confronted with patients who have recurrent attacks despite treatment with C1 esterase inhibitor concentrate or β2-receptor antagonists. The goal of this study was to investigate repeated attacks that occur 48 hours to 7 days (“cluster attacks”) after treatment, to determine why they occur and the factors that may be associated with them, and thus to prevent their occurrence. Methods: We conducted a multicenter mixed retrospective-prospective study with data acquired from all documented attacks in our patients with collective (n = 132) between 2015 and 2018. Results: Eighty-five percent (n = 132) of our total patient collective (N = 156) agreed to participate in the study. Nine percent of these patients (n = 12) had cluster attacks, with a total of 48 cluster attacks. The data procured from the patients were mixed retrospective‐prospective. Approximately 72% of all the cluster attacks were caused by exogenous stimuli (41% due to psychological stress, 29% due to physical stimuli, and 2% due to menstruation). Cluster attacks occurred in 7% of the patients who received prophylactic therapy in comparison with 12.5% of patients who received on-demand therapy. Cluster attacks comprised 48.4% of all the attacks that patients with cluster-attacks (n= 9) experienced. In addition, the patients who were underdosing their C1 esterase inhibitor treatment had cluster attacks more often. A lower “time to repeated attack” was seen in the patients who received on-demand therapy compared with those who received prophylactic therapy. Discussion: The percentage of the patients who had attacks as a result of exogenous triggers was higher in the cluster-attack group (70.5%) compared with the general HAE population (30‐42%). Repeated attacks, therefore, were strongly associated with external triggers. The patients who received prophylactic treatment and who experienced cluster attacks were highly likely to have been underdosing, which may explain the repeated attacks despite treatment. In the patients prone to cluster attacks, prophylaxis should be considered.


Sign in / Sign up

Export Citation Format

Share Document